PREHOSPITAL TRIAGE OF INTRACRANIAL HEMORRHAGE AND ANTERIOR LARGE VESSEL OCCLUSION ISCHEMIC STROKE:

THE VALUE OF THE RAPID ARTERIAL OCCLUSION EVALUTION

Luuk Dekker (MD)¹; Victor J. Geraedts (MD, PhD)^{1,2}; Jeroen Hubert (PhD)³; Dion Duijndam⁴; Marcel D.J. Durieux⁵; Loes Janssens (MD, PhD)^{4,6}; Wouter A. Moojen (MD, PhD)^{7,8,9}; Erik W. van Zwet (PhD)¹⁰; M.J.H. Wermer (MD, PhD)^{1,11}; Nyika D. Kruyt (MD, PhD)^{1,11}; Ido R. van den Wijngaard (MD, PhD)^{1,11,12}

Author affiliations

¹ Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands

² Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands

³ Institute of Biology, Leiden University, Leiden, the Netherlands

⁴ Emergency Medical Services Haaglanden, The Hague, the Netherlands

⁵ Emergency Medical Services Hollands-Midden, Leiden, the Netherlands

⁶ Emergency Department, Reinier de Graaf Gasthuis, Delft, the Netherlands

⁷ Department of Neurosurgery, Haaglanden Medical Center, The Hague, the Netherlands

⁸ Department of Neurosurgery, Haga Teaching Hospital, The Hague, the Netherlands

⁹ Department of Neurosurgery, Leiden University Medical Center, Leiden, Netherlands

¹⁰ Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the

Netherlands

¹¹ University NeuroVascular Center (UNVC) Leiden-The Hague

¹² Department of Neurology, Haaglanden Medical Center, The Hague, the Netherlands

Corresponding author:

Luuk Dekker, MD, Department of Neurology, Leiden University Medical Center, P.O. Box

9600, 2300 RC, Leiden; Email: l.dekker@lumc.nl; Phone: +31(0)715262895; ORCID iD:

2

https://orcid.org/0000-0002-0958-2081

Article type: Original article

Title character count: 98 (subtitle: 51)

Short title: RACE for ICH and aLVO triage

Number of tables: 3

Number of figures: 1

Number of references: 41

Total word count: 5834

Number of supplemental tables: 3

Number of supplemental figures: 1

Keywords: prehospital triage, stroke, ischemic stroke, hemorrhagic stroke, intracerebral hemorrhage, intracranial hemorrhage, large vessel occlusion, endovascular thrombectomy

ABSTRACT

Background: The Rapid Arterial oCclusion Evaluation (RACE) score can identify patients

with anterior circulation large vessel occlusion (aLVO) ischemic stroke for transportation to a

comprehensive stroke center for endovascular thrombectomy. However, patients with

intracranial hemorrhage (ICH) may also benefit from direct transportation to a comprehensive

stroke center for neurosurgical treatment. We aimed to assess if the RACE score can

distinguish patients with ICH in addition to aLVO stroke from other suspected stroke patients.

Methods: We analyzed data from the Leiden Prehospital Stroke Study: a multicenter,

prospective, observational cohort study in two Dutch ambulance regions. Ambulance

paramedics documented prehospital observations in all patients ≥18 years with suspected

stroke. We calculated the sensitivity, specificity, positive predictive value (PPV) and negative

predictive value (NPV) of a positive RACE score (≥5 points) for a diagnosis of ICH or aLVO

stroke, compared to patients with non-aLVO stroke, TIA, or stroke mimic. Additionally, we

performed a multivariable logistic regression analysis and calculated adjusted odds ratios

(aOR).

Results: We included 2004 stroke code patients, of whom 149 had an ICH, 153 an aLVO

stroke, 687 a non-aLVO stroke, 262 a TIA and 753 a stroke mimic. Patients with ICH and

aLVO stroke more often had a positive RACE score than other suspected stroke patients

(respectively 46.2% and 58.0% vs. 6.4%, p<0.01). A positive RACE score had a sensitivity of

52.7%, specificity of 93.6%, PPV of 55.4% and NPV of 92.9% for a diagnosis of ICH or

aLVO stroke. In multivariable analysis, a positive RACE score had the strongest association

4

with ICH or aLVO stroke (aOR 10.11, 95% CI 6.84-14.93).

Conclusions and Relevance: Our study shows that the RACE score can also identify patients with ICH in addition to aLVO stroke. This emphasizes the potential of the RACE for improving prehospital triage and allocation of stroke patients.

Non-standard Abbreviations and Acronyms

aLVO = anterior circulation large vessel occlusion

aOR = adjusted odds ratio

AVPU = Alert/Verbal/Pain/Unresponsive

CI = confidence interval

CSC = comprehensive stroke center

EMS = emergency medical services

EVT = endovascular thrombectomy

ICH = intracranial hemorrhage

IVT = intravenous thrombolysis

LPSS = Leiden Prehospital Stroke Study

mRS = modified Rankin Scale

NIHSS = National Institutes of Health Stroke Scale

5

NPV = negative predictive value

PPV = positive predictive value

PSC = primary stroke center

RACE = Rapid Arterial oCclusion Evaluation

INTRODUCTION

Stroke is a leading cause of death and disability worldwide.¹ The majority of strokes are ischemic, which can be treated with intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT). The efficacy of both IVT and EVT is highly time sensitive.²⁻⁴ IVT can be administered in all stroke centers, but is less effective in patients with an underlying anterior circulation large vessel occlusion (aLVO).⁵ In contrast, EVT is very effective in these patients, but is restricted to comprehensive stroke centers (CSC). aLVO patients who are first presented in a primary stroke center (PSC) therefore require subsequent transfer to a CSC, resulting in treatment delays and worse clinical outcomes.⁶⁻⁸

Treatment options for hemorrhagic stroke have been limited so far. However, it is becoming increasingly clear that fast initiation of treatment, including blood pressure management and reversal of coagulopathy, also improves outcomes in these patients. Although the exact role of surgery is still unclear, a recent meta-analysis showed that it is more effective when performed shorter after onset. Moreover, new techniques such as minimally invasive surgery are promising and also demonstrated better results when performed earlier. Similarly, timely neurosurgical interventions may be necessary in other types of intracranial hemorrhage (ICH) as well, including subarachnoid or traumatic hemorrhages.

These neurosurgical interventions are also restricted to CSCs, which stresses the importance of prehospital recognition of ICH alongside aLVO stroke patients for direct transportation to a CSC. Previous studies have shown that certain demographic characteristics and clinical observations, e.g. advanced age, use of oral anticoagulation, decreased consciousness, vomiting and elevated blood pressure, are associated with ICH. However, sample sizes of these studies were generally small and they often assessed only a few features.

Furthermore, other studies demonstrated that it is difficult to specifically identify ICH patients based solely on clinical assessment, and that current triage scores are insufficient. 22-26 Concerning the triage of aLVO patients, studies comparing several clinical scales demonstrated that the Rapid Arterial oCclusion Evaluation (RACE) score performs relatively well. 27-29 However, it is yet unclear if the RACE score can also be used for recognition of ICH patients. Therefore, we aim to 1) assess the utility of the RACE score for prehospital identification of patients with ICH in addition to aLVO stroke, and 2) to compare the RACE to other demographic characteristics and clinical observations that have been shown to distinguish patients with ICH or aLVO stroke from patients with non-aLVO ischemic stroke, TIA or stroke mimic.

METHODS

Study population and data collection

We used data from the Leiden Prehospital Stroke Study (LPSS), a large prospective, multicenter, observational cohort study in two Emergency Medical Services (EMS) regions in the Netherlands. These regions encompass 4 PSCs and 3 CSCs, serving approximately 2 million inhabitants.²⁷ The study included all patients ≥18 years old for whom an EMS-initiated acute stroke code was activated between July 2018 and October 2019. EMS paramedics were registered nurses with specialized training in ambulance care, who activated a stroke code based on a positive Face-Arm-Speech Time (FAST) test or other (focal) neurological symptoms at the discretion of the individual paramedics. Policy was to transport patients to the nearest hospital (PSC or CSC) if onset was <6 hours before presentation, and to the nearest CSC if onset was between 6 and 24 hours. Paramedics routinely documented patient characteristics and clinical observations in electronic transport records, including

glucose level, assessment of consciousness with AVPU (Alert/Verbal/Pain/Unresponsive) score and Glasgow Coma Scale, pupillary assessment, and presence of nausea/vomiting. For the LPSS an additional web-based application containing 10 to 13 structured clinical items derived from the National Institutes of Health Stroke Scale (NIHSS) was filled in for each patient.³⁰ This enabled the prehospital reconstruction of several aLVO scales including the RACE. The RACE encompasses six clinical observations (facial palsy, arm and leg motor deficits, gaze deviation and either agnosia or aphasia), resulting in a score of 0 to 9 points. A RACE score of \geq 5 points was considered positive.²⁹ Corresponding electronic patient records from the hospitals were used to extract medical history, medication use, admission NIHSS score, data on neuroimaging including location of ICH and aLVO, final diagnosis after 3 months, and functional outcome after 3 months using the modified Rankin Scale (mRS).³¹ ICH were categorized based on the underlying cause and location as either primary hemorrhages, including deep, lobar or posterior fossa intraparenchymal hemorrhages, subarachnoid hemorrhages or intraventricular hemorrhages, or as secondary traumatic hemorrhages. aLVO was defined as an occlusion of the internal carotid artery, M1 or M2-part of the middle cerebral artery or A1 or A2-part of the anterior cerebral artery. Patients with missing transport records, unutilized web-based applications or missing hospital records were excluded. We used the STROBE guidelines for reporting this observational study (**Table S1**).³²

Statistical analysis

Patients were categorized into three groups based on their final diagnosis: 1) ICH; 2) aLVO stroke; or 3) other (non-aLVO stroke, TIA or stroke mimic). Independent t-tests and chi-square tests were used to compare baseline characteristics between the three groups. For our first aim, we calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of a positive RACE score for a diagnosis of ICH or aLVO stroke. To

explore how use of the RACE for direct transportation to a CSC might influence patient allocation, we provided a hypothetical example in our cohort. For our second aim, we conducted multivariable logistic regression analyses to investigate associations of other demographic characteristics and prehospital EMS observations with a diagnosis of ICH or aLVO stroke, and to compare these with the RACE score. These characteristics and observations were selected based upon previous literature, and included age, sex, history of atrial fibrillation, use of oral anticoagulation, mean arterial blood pressure, glucose level, consciousness as measured with the AVPU and Glasgow Coma Scale, pupillary assessment, and presence of nausea/vomiting. ^{16-22,33} We calculated adjusted odds ratios (aOR) with 95% confidence intervals (CI) to determine associations with a final diagnosis of ICH or aLVO stroke, with the RACE score as (a) a dichotomized variable (positive ≥5 points or negative <5 points) and (b) as a categorical variable ranging from 0 to 9 points. A 2-sided p-value of ≤0.05 was considered statistically significant.

Missing data

For patients in whom one or more items of the RACE were untestable or missing, we assessed if the cut-off of ≥5 was already reached with the points scored in documented items (positive), or if the score would still be less than 5 even when assigning maximal scores to missing items (negative). Patients in whom it could not be determined if the RACE was positive or negative were excluded from analysis of sensitivity, specificity, PPV and NPV of the RACE. In case a history of atrial fibrillation or use of oral anticoagulation was not documented by EMS personnel, this was extracted from hospital records. For multivariable analyses, missing data including RACE scores were filled using multiple imputation by chained equations (MICE) with five imputations. Variables used during MICE constituted of all variables used in the multivariable analyses and the final diagnosis. We used Rubin's rules to pool outcomes of the multivariable analyses from the five imputations.

Outcomes

Primary outcomes were the sensitivity, specificity, PPV and NPV of the RACE score for ICH or aLVO stroke. Secondary outcome was the aOR of the RACE compared to other characteristics and observations in multivariable analysis.

RESULTS

Of 2812 acute stroke codes activated, 808 (28.7%) were excluded because no web-based application was used by EMS (n=752), or hospital records (n=53) or transport records (n=3) were missing. In a previous analysis, patients in whom the application was not used had similar baseline characteristics, incidence of aLVO, and stroke severity, but slightly more often an ICH (12.0% vs. 7.4%) or stroke mimic (44.6% vs. 37.5%) compared with included patients.²⁷

Of the 2004 included stroke code patients, 149 (7.4%) had an ICH, 153 (7.6%) an aLVO stroke, and 1702 (84.9%) other diagnoses (687 non-aLVO stroke, 262 TIA and 753 stroke mimic) (**Figure 1**). In total, 780 (38.9%) were first presented in a PSC and 1224 (61.1%) in a CSC. Of the 149 ICH patients, 130 (87.2%) had a primary hemorrhage of which 116 were intraparenchymal, 13 subarachnoid and 1 intraventricular, and 19 had a secondary traumatic hemorrhage. Thirty-eight (25.5%) were presented in a PSC and 111 (74.5%) in a CSC. Of the 153 aLVO stroke patients, 31 (20.3%) were first transported to a PSC, and 98 (64.1%) underwent EVT. Of these EVT-treated patients, 25 were initially presented in a PSC and subsequently transferred to a CSC (**Table 1**).

Atrial fibrillation was more common in patients with ICH (21.8%) and aLVO stroke (18.8%) compared to other patients (12.6%, p<0.01 and p=0.03 respectively). Furthermore,

ICH patients more often had a history of previous intracranial hemorrhage (respectively 9.5% vs. 1.3% and 3.9%, both p<0.01) and used oral anticoagulation (27.6% vs. 14.6% and 16.4%, both p<0.01) than patients with aLVO stroke or other diagnoses (**Table 1**, **Table S2**). Concerning EMS observations, ICH patients had higher blood pressure (median 178/98 vs. 155/90 and 159/90 mmHg respectively, both p<0.01), and more often an abnormal pupillary assessment (respectively 8.1% vs. 3.9% and 1.6%, p=0.13 and <0.01) and nausea/vomiting (65.0% vs. 41.2% and 52.3%, p=0.03 and 0.06) than patients with aLVO stroke or other diagnoses. Also, patients with ICH and to a lesser extent aLVO stroke more often had a decreased consciousness, scoring a Verbal/Pain/Unresponsive on the AVPU score (38.3% vs. 23.5% vs. 11.2%, p<0.01 for all differences) and less points on the Glasgow Coma Scale (<15 points: 43.9% and 32.0% vs. 18.8%; both p<0.01) than patients with other diagnoses (**Table 1**, **Table S2**). Statistical analysis of differences between the three groups can be found in **Table S2**, and further specification of characteristics of patients with non-aLVO stroke, TIA or stroke mimic in **Table S3**.

It was possible to determine a positive or negative RACE score in 1565 (78.1%) patients. Patients with ICH or aLVO stroke more often had a positive RACE score than patients with other diagnoses (46.2% and 58.0% vs. 6.4%, both p<0.01) (**Table 1, Table S2**). When combining the groups of ICH and aLVO stroke patients, a positive RACE score had a sensitivity of 52.7%, specificity of 93.6%, PPV of 55.4%, and NPV of 92.9% (**Table 2**). Hypothetically, if the RACE would have been applied to our cohort in an urban region with a relatively high proportion of CSCs and short distances between PSCs and CSCs, 9 of the 38 ICH patients and 17 of the 31 aLVO stroke patients (15 treated with EVT) who were first presented in a PSC would have benefited from direct allocation to a CSC. Thirty-nine patients with other diagnoses would have unnecessarily bypassed a closer PSC for transport to a CSC, including 18 non-aLVO stroke patients who received IVT.

In multivariable analyses, male sex, higher mean arterial pressure and higher RACE scores were significantly associated with ICH or aLVO stroke (**Table 3, Figure S1**). A positive RACE score had strongest association with ICH or aLVO stroke (aOR 10.11, 95% CI 6.84-14.93) (**Table 3a**).

DISCUSSION

Our findings show that a positive RACE score is associated with both ICH and aLVO stroke, whilst the predictive value of other demographic characteristics and EMS observations is limited. The promising future treatment options for ICH and increasing use of EVT emphasize the growing need for adequate identification of stroke patients that require direct transportation to a CSC. 11-14,35,36 This study demonstrates the potential of the RACE for optimizing prehospital triage and subsequently minimizing treatment delays and improving outcomes for both ICH and aLVO stroke patients.

Whilst outcomes of patients with ischemic stroke have significantly improved due to the impact of reperfusion therapies, treatment options for hemorrhagic stroke have remained limited and prognosis has not clearly changed over the last 20 years.³⁷ However, results of recent studies investigating minimally invasive surgery in the acute phase are encouraging and multiple trials are ongoing (ENRICH, NCT02880878; DIST, NCT03608423; MIND, NCT03342664; INVEST, NCT02654015).¹¹⁻¹⁴ This stresses the importance of prehospital identification of ICH patients alongside aLVO stroke patients. Previous studies that aimed to distinguish patients with ICH from other diagnoses based on clinical findings have been disappointing.²²⁻²⁶ However, our study suggests that the RACE score could help identify these patients. Although its sensitivity was lower for ICH than for aLVO stroke (46.2% vs. 58.0%), it is likely that this is caused by patients with smaller hemorrhages and concomitantly less

deficits having a false negative RACE score. However, in these patients surgical interventions are less often indicated and transportation to a CSC less urgent. Furthermore, the limited prevalence of ICH and aLVO strokes in our population may well explain the relatively low PPV (55.4%).

Use of the RACE score in our cohort would have hypothetically implicated that 18 IVT-treated non-aLVO stroke patients bypassed a closer PSC, whilst 15 EVT-treated aLVO patients and 9 ICH patients would have been directly allocated to a CSC. Set aside the possible benefit for ICH patients, this may well have led to improved outcomes since the additional time required for an interhospital transfer is generally much higher than the additional transport time to a CSC, and a reduction in delay to EVT usually outweighs a similar time reduction to IVT. 7,8,38-40

In multivariable analysis, most other variables were not significantly associated with ICH or aLVO stroke and may be of limited use for triage in clinical practice. This is in line with previous studies that reported poor results of scoring systems that tried to identify ICH patients based on demographic characteristics and clinical observations, which often also included atrial fibrillation, level of consciousness and nausea/vomiting. 22-26 Surprisingly, a decreased consciousness (Verbal/Pain/Unresponsive on the AVPU score or decrease in points on the Glasgow Coma Scale) was not associated with ICH or aLVO stroke in multivariable analysis, whilst this was more common in these patients. However, we found that this was due to its strong correlation with the RACE score, which overshadowed and inversed the effect of a decreased consciousness.

Strengths of this study include the large sample size, number of characteristics assessed and prospective collection of data. Because of this, the overall amount of missing data was limited and extensive evaluation of characteristics was possible. Furthermore, the

study design was very pragmatic, including all stroke code patients, using clinical observations from paramedics on-site, and analyzing the whole group of ICH and aLVO stroke patients, which represent all patients who require direct transportation to a CSC. This makes results well generalizable and useful for routine practice.

However, our study has some limitations. Firstly, some patients were excluded because the application was not used or hospital or transport records were missing. Those excluded had a slightly higher incidence of ICH, which may have underestimated the PPV and the hypothetical implications of use of the RACE score in our cohort. Secondly, it was not possible to reconstruct the RACE score in approximately 20% of patients due to one or more missing observations of its six clinical items. This may also have reduced the implications of the RACE in our hypothetical example, and we used MICE for completing data for multivariable analyses. Thirdly, a possible history of atrial fibrillation was not routinely documented in EMS transport records and therefore extracted from hospital records. In practice, it may be difficult to obtain this information in an emergency setting, although information concerning use of anticoagulation is generally well known by EMS. Fourthly, data on neuroimaging data, including the presence, location and size of ICH and occlusions, was also collected from hospital records and not reviewed by an independent core lab. Finally, although we focused on ICH and aLVO stroke patients, other patients may also benefit from direct transportation to a CSC, such as patients with a posterior circulation occlusion. 41 However, this was beyond the scope of the current study.

CONCLUSIONS

Our study shows that a positive RACE score is strongly associated with both ICH and aLVO stroke, while other demographic characteristics and prehospital observations have limited

value for distinguishing these patients. This highlights the potential of the RACE for

optimizing prehospital triage and subsequent allocation of stroke patients, and emphasizes the

importance of its implementation in routine practice.

Acknowledgements: We thank all the participants, site personnel, and local staff for making

this study possible.

Sources of Funding: The original LPSS study was funded by grants from the Dutch Brain

Foundation, Dutch Innovation Fund and Health~Holland. This substudy received no

additional funding.

Disclosures: MJHW reported receiving Clinical Established Investigator grant 2016T086

from the Dutch Heart Foundation and VIDI grant 9171337 from the Netherlands Organization

for Health Research and Development (ZonMw) during the conduct of the original LPSS

study. NDK reported receiving grant HA20 15.01.02 from the Dutch Brain Foundation, grant

3.240 from the Dutch Innovation Fund, and grant LSHM16041 from Health~Holland, which

were used for funding the original LPSS study. No other conflicts of interests or disclosures

were reported.

Author Contributions: IvdW and NK conceptualized the study. LD and DD acquired data.

EvZ consulted in statistical analyses and LD, VG, JH and EvZ carried out analyses. LD had

full access to all the data in the study and takes responsibility for its integrity and the data

analysis. LD drafted the manuscript. All authors critically critically revised the manuscript

and approved the final version.

Ethical Approval and Informed Consent: The institutional review boards of the Leiden

University Medical Center and of the participating hospitals approved the original LPSS

study. The need for obtaining informed consent was waived because the extent of effort

required by the large number of health care providers was disproportionate compared with the

relatively limited sensitivity of the collected data and intrusion to the personal privacy. The

original study was registered with ClinicalTrials.gov (identifier: NCT04442659).

Data Availability Statement: In compliance with Dutch law, patient data cannot be made

available, since participants were not informed during the opt-out procedure about the public

sharing of their individual participant data in de-identified form. The syntax and output files

of the statistical analyses can be made available from the corresponding author upon

17

reasonable request.

Supplemental Material

Tables S1-S3

Figure S1

REFERENCES

- Collaborators GS. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18:439-458. doi: 10.1016/S1474-4422(19)30034-1
- 2. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis.

 *Jama. 2016;316:1279-1288. doi: 10.1001/jama.2016.13647
- Mulder MJHL, Jansen IGH, Goldhoorn RB, Venema E, Chalos V, Compagne KCJ, Roozenbeek B, Lingsma HF, Schonewille WJ, van den Wijngaard IR, et al. Time to Endovascular Treatment and Outcome in Acute Ischemic Stroke: MR CLEAN Registry Results. Circulation. 2018;138:232-240. doi: 10.1161/CIRCULATIONAHA.117.032600
- 4. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. *Jama*. 2013;309:2480-2488. doi: 10.1001/jama.2013.6959
- 5. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, Watson T, Goyal M, Demchuk AM. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action.

 Stroke. 2010;41:2254-2258. doi: 10.1161/STROKEAHA.110.592535
- 6. Venema E, Groot AE, Lingsma HF, Hinsenveld W, Treurniet KM, Chalos V, Zinkstok SM, Mulder M, de Ridder IR, Marquering HA, et al. Effect of Interhospital Transfer

- on Endovascular Treatment for Acute Ischemic Stroke. *Stroke*. 2019;50:923-930. doi: 10.1161/STROKEAHA.118.024091
- 7. Froehler MT, Saver JL, Zaidat OO, Jahan R, Aziz-Sultan MA, Klucznik RP, Haussen DC, Hellinger FR, Jr., Yavagal DR, Yao TL, et al. Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the **STRATIS** (Systematic **Patients** Registry Evaluation of Treated Neurothrombectomy Devices Acute Ischemic Stroke). Circulation. 2017;136:2311-2321. doi: 10.1161/CIRCULATIONAHA.117.028920
- 8. Shah S, Xian Y, Sheng S, Zachrison KS, Saver JL, Sheth KN, Fonarow GC, Schwamm LH, Smith EE. Use, Temporal Trends, and Outcomes of Endovascular Therapy After Interhospital Transfer in the United States. *Circulation*. 2019;139:1568-1577. doi: 10.1161/circulationaha.118.036509
- McGurgan IJ, Ziai WC, Werring DJ, Al-Shahi Salman R, Parry-Jones AR. Acute intracerebral haemorrhage: diagnosis and management. *Pract Neurol.* 2020;21:128-136. doi: 10.1136/practneurol-2020-002763
- Sondag L, Schreuder F, Boogaarts HD, Rovers MM, Vandertop WP, Dammers R,
 Klijn CJM. Neurosurgical Intervention for Supratentorial Intracerebral Hemorrhage.
 Annals of neurology. 2020;88:239-250. doi: 10.1002/ana.25732

- Zheng Z, Wang Q, Sun S, Luo J. Minimally Invasive Surgery for Intracerebral and Intraventricular Hemorrhage. Frontiers in neurology. 2022;13:755501. doi: 10.3389/fneur.2022.755501
- 13. Zhou X, Xie L, Altinel Y, Qiao N. Assessment of Evidence Regarding Minimally Invasive Surgery vs. Conservative Treatment on Intracerebral Hemorrhage: A Trial Sequential Analysis of Randomized Controlled Trials. Frontiers in neurology. 2020;11:426. doi: 10.3389/fneur.2020.00426
- Scaggiante J, Zhang X, Mocco J, Kellner CP. Minimally Invasive Surgery for Intracerebral Hemorrhage. Stroke. 2018;49:2612-2620. doi: 10.1161/strokeaha.118.020688
- 15. Kellner CP, Song R, Ali M, Nistal DA, Samarage M, Dangayach NS, Liang J, McNeill I, Zhang X, Bederson JB, et al. Time to Evacuation and Functional Outcome After Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation. *Stroke*. 2021;52:e536-e539. doi: 10.1161/strokeaha.121.034392
- 16. Poungvarin N, Viriyavejakul A, Komontri C. Siriraj stroke score and validation study to distinguish supratentorial intracerebral haemorrhage from infarction. *BMJ (Clinical research ed)*. 1991;302:1565-1567. doi: 10.1136/bmj.302.6792.1565
- 17. Allen CM. Clinical diagnosis of the acute stroke syndrome. *Q J Med.* 1983;52:515-523. doi:
- 18. Besson G, Robert C, Hommel M, Perret J. Is it clinically possible to distinguish nonhemorrhagic infarct from hemorrhagic stroke? *Stroke*. 1995;26:1205-1209. doi: 10.1161/01.str.26.7.1205
- 19. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. *Stroke*. 1995;26:1471-1477. doi: 10.1161/01.str.26.8.1471

- 20. Kim TJ, Park SH, Jeong HB, Ha EJ, Cho WS, Kang HS, Kim JE, Ko SB. Neurological Pupil Index as an Indicator of Neurological Worsening in Large Hemispheric Strokes. *Neurocritical care*. 2020;33:575-581. doi: 10.1007/s12028-020-00936-0
- 21. Massaro AR, Sacco RL, Scaff M, Mohr JP. Clinical discriminators between acute brain hemorrhage and infarction: a practical score for early patient identification. *Arq Neuropsiquiatr*. 2002;60:185-191. doi: 10.1590/s0004-282x2002000200001
- 22. Runchey S, McGee S. Does this patient have a hemorrhagic stroke?: clinical findings distinguishing hemorrhagic stroke from ischemic stroke. *Jama*. 2010;303:2280-2286. doi: 10.1001/jama.2010.754
- 23. Mwita CC, Kajia D, Gwer S, Etyang A, Newton CR. Accuracy of clinical stroke scores for distinguishing stroke subtypes in resource poor settings: A systematic review of diagnostic test accuracy. *J Neurosci Rural Pract.* 2014;5:330-339. doi: 10.4103/0976-3147.139966
- 24. Hawkins GC, Bonita R, Broad JB, Anderson NE. Inadequacy of clinical scoring systems to differentiate stroke subtypes in population-based studies. *Stroke*. 1995;26:1338-1342. doi: 10.1161/01.str.26.8.1338
- 25. Weir CJ, Murray GD, Adams FG, Muir KW, Grosset DG, Lees KR. Poor accuracy of stroke scoring systems for differential clinical diagnosis of intracranial haemorrhage and infarction. *Lancet (London, England)*. 1994;344:999-1002. doi: 10.1016/s0140-6736(94)91648-9
- 26. Connor MD, Modi G, Warlow CP. Accuracy of the Siriraj and Guy's Hospital Stroke Scores in urban South Africans. Stroke. 2007;38:62-68. doi: 10.1161/01.Str.0000251853.62387.68

- 27. Nguyen TTM, van den Wijngaard IR, Bosch J, van Belle E, van Zwet EW, Dofferhoff-Vermeulen T, Duijndam D, Koster GT, de Schryver E, Kloos LMH, et al. Comparison of Prehospital Scales for Predicting Large Anterior Vessel Occlusion in the Ambulance Setting. *JAMA Neurol*. 2020. doi: 10.1001/jamaneurol.2020.4418
- Duvekot MHC, Venema E, Rozeman AD, Moudrous W, Vermeij FH, Biekart M, Lingsma HF, Maasland L, Wijnhoud AD, Mulder L, et al. Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study. *The Lancet Neurology*. 2021;20:213-221. doi: 10.1016/S1474-4422(20)30439-7
- 29. Perez de la Ossa N, Carrera D, Gorchs M, Querol M, Millan M, Gomis M, Dorado L, Lopez-Cancio E, Hernandez-Perez M, Chicharro V, et al. Design and validation of a prehospital stroke scale to predict large arterial occlusion: the rapid arterial occlusion evaluation scale. Stroke. 2014;45:87-91. doi: 10.1161/STROKEAHA.113.003071
- 30. Brott T, Adams HP, Jr., Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al. Measurements of acute cerebral infarction: a clinical examination scale. *Stroke*. 1989;20:864-870. doi:
- 31. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke*. 1988;19:604-607. doi:
- 32. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet (London, England)*. 2007;370:1453-1457. doi: 10.1016/s0140-6736(07)61602-x
- Pagola J, Juega J, Francisco-Pascual J, Bustamante A, Penalba A, Pala E, RodriguezM, De Lera Alfonso M, Arenillas JF, Cabezas JA, et al. Large vessel occlusion is

- independently associated with atrial fibrillation detection. *European journal of neurology*. 2020;27:1618-1624. doi: 10.1111/ene.14281
- 34. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? *Int J Methods Psychiatr Res.* 2011;20:40-49. doi: 10.1002/mpr.329
- 35. McMeekin P, Flynn D, James M, Price CI, Ford GA, White P. Updating estimates of the number of UK stroke patients eligible for endovascular thrombectomy: incorporating recent evidence to facilitate service planning. *Eur Stroke J.* 2021;6:349-356. doi: 10.1177/23969873211059471
- 36. Rai AT, Link PS, Domico JR. Updated estimates of large and medium vessel strokes, mechanical thrombectomy trends, and future projections indicate a relative flattening of the growth curve but highlight opportunities for expanding endovascular stroke care. *Journal of neurointerventional surgery*. 2022. doi: 10.1136/jnis-2022-019777
- 37. Toyoda K, Yoshimura S, Nakai M, Koga M, Sasahara Y, Sonoda K, Kamiyama K, Yazawa Y, Kawada S, Sasaki M, et al. Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes. *JAMA Neurol.* 2022;79:61-69. doi: 10.1001/jamaneurol.2021.4346
- 38. McTaggart RA, Moldovan K, Oliver LA, Dibiasio EL, Baird GL, Hemendinger ML, Haas RA, Goyal M, Wang TY, Jayaraman MV. Door-in-Door-Out Time at Primary Stroke Centers May Predict Outcome for Emergent Large Vessel Occlusion Patients.

 Stroke. 2018;49:2969-2974. doi: 10.1161/strokeaha.118.021936
- 39. Meretoja A, Keshtkaran M, Saver JL, Tatlisumak T, Parsons MW, Kaste M, Davis SM, Donnan GA, Churilov L. Stroke thrombolysis: save a minute, save a day. *Stroke*. 2014;45:1053-1058. doi: 10.1161/STROKEAHA.113.002910

- 40. Meretoja A, Keshtkaran M, Tatlisumak T, Donnan GA, Churilov L. Endovascular therapy for ischemic stroke: Save a minute-save a week. *Neurology*. 2017;88:2123-2127. doi: 10.1212/WNL.0000000000003981
- 41. Xu J, Chen X, Chen S, Cao W, Zhao H, Ni W, Zhang Y, Gao C, Gu Y, Cheng X, et al. Endovascular treatment for basilar artery occlusion: a meta-analysis. *Stroke Vasc Neurol*. 2022:svn-2022-001740. doi: 10.1136/svn-2022-001740

TABLES

Table 1. Characteristics of patients with either intracranial hemorrhage, aLVO stroke or other diagnoses

	Total (n=2004)	Intracranial hemorrhage (n=149)	aLVO stroke (n=153)	Other* (n=1702)
Demographic characteristics				
Age, mean (SD), years	71.1 (14.9)	73.7 (13.2)	72.7 (13.0)	70.7 (15.1)
Sex, male	1020/2004 (50.9%)	82/149 (55.0%)	90/153 (58.8%)	848/1702 (49.8%)
Presentation				
PSC	780/2004 (38.9%)	38/149 (25.5%)	31/153 (20.3%)	711/1702 (41.8%)
CSC	1224/2004 (61.1%)	111/149 (74.5%)	122/153 (79.7%)	991/1702 (58.2%)
Pre-morbid mRS ≤2	1566/1833 (85.4%)	119/149 (79.9%)	123/135 (91.1%)	1324/1549 (85.5%)
Wake-up/unknown time of symptom onset	326/1604 (20.3%)	16/102 (15.7%)	46/149 (30.9%)	264/1353 (19.5%)
Onset-to-EMS-arrival time, median (IQR), minutes	93 (32-276)	91 (20-332)	92 (17-305)	93 (34-273)
Onset-to-door time, median (IQR), minutes	119 (61-300)	118 (51-352)	115 (45-324)	119 (64-300)
Medical history & medication				
Atrial fibrillation	272/1982 (13.7%)	32/147 (21.8%)	28/149 (18.8%)	212/1686 (12.6%)
Intracranial hemorrhage	83/1995 (4.2%)	14/147 (9.5%)	2/148 (1.3%)	67/1698 (3.9%)
Ischemic stroke or TIA	670/1984 (33.8%)	36/146 (24.7%)	32/150 (21.3%)	602/1688 (35.7%)
Diabetes mellitus	420/1983 (21.2%)	23/147 (15.6%)	36/150 (24.0%)	361/1686 (21.4%)
Epilepsy	106/2004 (5.3%)	4/149 (2.7%)	4/153 (2.6%)	98/1702 (5.8%)
Use of oral anticoagulation	336/1964 (17.1%)	40/145 (27.6%)	22/151 (14.6%)	274/1668 (16.4%)
Use of antiplatelet medication	689/1974 (34.9%)	42/145 (29.0%)	49/151 (32.5%)	598/1678 (35.6%)
EMS observations				
Blood pressure, median (IQR), mm Hg				
Systolic	160 (141-182)	178 (155-197)	155 (138-178)	159 (141-181)
Diastolic	90 (80-102)	98 (86-110)	90 (80-101)	90 (80-101)
Glucose level, median (IQR), mmol/L	6.5 (5.5-7.8)	6.9 (5.7-8.4)	6.6 (5.5-8.0)	6.4 (5.5-7.8)
Abnormal AVPU score (Verbal/Pain/Unresponsive)	283/2004 (14.1%)	57/149 (38.3%)	36/153 (23.5%)	190/1702 (11.2%)
Abnormal Glasgow Coma Scale (<15 points)	433/1995 (21.7%)	65/148 (43.9%)	49/153 (32.0%)	319/1694 (18.8%)
Eyes – not open spontaneously (<4)	169 (8.5%)	42 (28.4%)	21 (13.7%)	106 (6.3%)
Motor – does not execute commands (<6)	192 (9.6%)	44 (29.7%)	30 (19.6%)	118 (7.0%)
Verbal – not oriented (<5)	394 (19.7%)	59 (39.9%)	48 (31.4%)	287 (16.9%)
Abnormal pupillary assessment (anisocoria or not reactive to light)	46/2004 (2.3%)	12/149 (8.1%)	6/153 (3.9%)	28/1702 (1.6%)

Nausea/vomiting	370/700 (52.9%)	39/60 (65.0%)	14/34 (41.2%)	317/606 (52.3%)
RACE score positive (≥5 points)	195/1565 (12.5%)	43/93 (46.2%)	65/112 (58.0%)	87/1360 (6.4%)
In-hospital NIHSS score, median (IQR)	2 (0-5)	11 (4-18)	11 (5-17)	1 (0-4)
Imaging findings, treatment and				
outcome				
Primary intracranial hemorrhage		130 (87.2%)		
Intraparenchymal		116 (77.9%)		
Deep		65 (43.6%)		
Lobar		42 (28.2%)		
Posterior fossa (brainstem/cerebellum)		9 (6.0%)		
Subarachnoid		13 (8.7%)		
Intraventricular		1 (0.7%)		
Traumatic intracranial hemorrhage		19 (12.8%)		
Isolated subdural hematoma		13 (8.7%)		
Combined†		6 (4.0%)		
Large vessel occlusion	173 (8.6%)		153	20
Anterior circulation	153 (7.6%)		153	
Internal carotid artery			16 (10.5%)	
Middle cerebral artery M1			75 (49.0%)	
Middle cerebral artery M2			58 (37.9%)	
Anterior cerebral artery			4 (2.6%)	
Posterior circulation	19 (0.9%)			19 (95.0%)
Multiple occlusions‡	1 (0.1%)			1 (0.5%)
IVT	314 (15.7%)		63/153 (41.2%)	251/1702 (14.7%)
EVT	98 (4.9%)		98/153 (64.1%)	
transfer from PSC to CSC for EVT			25/98 (25.5%)	
mRS after 3 months ≤2	470/787 (59.7%)	27/103 (26.2%)	45/112 (40.2%)	398/572 (69.6%)

^{*} Other diagnoses include non-aLVO stroke, TIA and stroke mimic.

[†] Combined: hemorrhage on multiple locations (e.g. epidural, subdural, subarachnoid and/or intraparenchymal).

[‡] One patient had multiple occlusions in the anterior as well as posterior circulation.

Table 2. Sensitivity, specificity, PPV and NPV of a positive RACE score (≥5 points) for a diagnosis of intracranial hemorrhage or aLVO stroke

	Sensitivity	Specificity	PPV	NPV
ICH vs. all other diagnoses (aLVO stroke,	46.2%	89.7%	22.1%	96.4%
non-aLVO stroke, TIA and stroke mimic)	40.270	09.770	22.170	90.470
ICH vs. non-aLVO stroke, TIA and stroke	46.2%	93.6%	33.1%	96.2%
mimic (without aLVO stroke)	40.270	93.070	33.170	90.270
aLVO stroke vs. all other diagnoses (ICH,	58.0%	91.1%	33.3%	96.6%
non-aLVO stroke, TIA and stroke mimic)	36.070	91.170	33.370	90.070
aLVO stroke vs. non-aLVO stroke, TIA	58.0%	93.6%	42.8%	96.4%
and stroke mimic (without ICH)	36.070	93.070	42.070	90.470
ICH and aLVO stroke vs. non-aLVO	52.7%	93.6%	55.4%	92.9%
stroke, TIA and stroke mimic	32.170	93.070	33.470	94.970


Table 3. Multivariable regression analysis for diagnosis of ICH or aLVO stroke vs. other diagnoses

3a. Multivariable analysis with dichotomized RACE score	aOR for ICH or aLVO stroke (95% CI)*	p-value
Age, per year increase	1.00 (0.99-1.01)	0.72
Male sex	1.75 (1.30-2.35)	< 0.01
History of atrial fibrillation	1.49 (0.92-2.41)	0.10
Use of oral anticoagulation	1.02 (0.64-1.63)	0.93
Mean arterial pressure, per 10 mmHg increase	1.14 (1.07-1.22)	< 0.01
Glucose level, per 1 mmol/L increase†	1.04 (0.99-1.10)	0.16
Abnormal AVPU score (Verbal/Pain/Unresponsive)	0.98 (0.56-1.71)	0.94
Glasgow Coma Scale score, per point decrease from 15	1.02 (0.93-1.12)	0.73
Abnormal pupillary assessment	1.83 (0.87-3.85)	0.11
Nausea/vomiting	1.14 (0.67-1.94)	0.64
Positive RACE score (≥5 points)	10.11 (6.84-14.93)	< 0.01
21. Maldanial I. and hair aid and a deal DACE	aOR for ICH or aLVO	
3b. Multivariable analysis with categorical RACE score	stroke (95% CI)*	p-value
Age, per year increase	1.00 (0.99-1.01	0.90
Male sex	1.86 (1.37-2.54)	<0.01
History of atrial fibrillation	1.49 (0.90-2.48)	0.12
Use of oral anticoagulation	1.04 (0.63-1.71)	0.89
Mean arterial pressure, per 10 mmHg increase	1.15 (1.08-1.23)	<0.01
Glucose level, per 1 mmol/L increase†	1.03 (0.98-1.09)	0.22
Abnormal AVPU score (Verbal/Pain/Unresponsive)	0.81 (0.47-1.39)	0.44
Glasgow Coma Scale score, per point decrease from 15	0.97 (0.89-1.06)	0.53
Abnormal pupillary assessment	1.79 (0.82-3.89)	0.14
Nausea/vomiting	1.26 (0.70-2.26)	0.47
RACE score‡		
1	1.51 (0.85-2.67)	0.16
2	2.56 (1.44-4.57)	<0.01
3	2.65 (1.10-6.35)	0.04
4	7.92 (4.08-15.39)	<0.01
5	9.83 (4.98-19.42)	<0.01
6	14.80 (6.96-31.47)	<0.01
7	34.88 (17.15-70.92)	<0.01
8	43.60 (21.29-89.29)	<0.01
9	40.74 (16.30-101.84)	<0.01

- * Intercept of model 3a: 0.008 (95% CI 0.002-0.027); intercept of model 3b: 0.004 (95% CI 0.001-0.014).
- † Serum glucose SI conversion: 1 mmol/L = 18.02 mg/dL.
- ‡ Compared to a RACE score of 0.

FIGURES

Figure 1. Flowchart of included patients



EMS = emergency medical services; aLVO = anterior circulation large vessel occlusion; TIA

= transient ischemic attack